Society management

Instil Bio Announces Poster Presentations of the CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

DALLAS, November 08, 2022 (GLOBE NEWSWIRE) — Instill Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor-infiltrating lymphocytes, or TIL, therapies for the treatment of cancer patients, today announced the presentation of posters of preclinical data and ongoing trials. progress of the ongoing ITIL-306 Phase 1 clinical trial using the CoStimulatory Antigen Receptor (CoStAR) platform at 37e Annual meeting of the Cancer Immunotherapy Society (SITC), which will be held from November 8-12, 2022.

Preclinical data demonstrating CoStAR activity in physiologically relevant ranges of FRα expression and TCR affinity are presented in Poster 282. These data demonstrated that CoStAR amplified T cell responses at all expression levels of FRα as long as FRα was expressed, supporting the clinical exploration of ITIL-306 in multiple types of solid tumors with a variety of levels of expression of FRα. Moreover, cells expressing CoStAR do not respond to FRα in the absence of TCR stimulation, highlighting the expected safety profile of the CoStAR platform. Currently, ITIL-306 is being evaluated in a first-in-man dose-escalation Phase 1 clinical study for the treatment of refractory solid tumors with the first patient dosed in October 2022.

The company also features an ongoing trial poster summarizing the design of the ongoing ITIL-306 Phase 1 study (Poster 776). ITIL-306-201 is a Phase 1 multicenter, single-arm, dose escalation and expansion study evaluating the safety and feasibility of ITIL-306 in adult female patients with epithelial cancer of the advanced ovarian (ECC) and non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC) that has relapsed or is refractory to ≥ 1 prior line of systemic therapy. It is important to note that the phase 1 study of ITIL-306 presents a treatment regimen without high-dose interleukin-2.

The details of the poster presentations are as follows:

Title: CoStimulatory Antigen Receptor (CoStAR) anti-folate alpha (FRα) receptor enhances T-cell function within physiologically relevant ranges of FRα expression and T-cell receptor (TCR) affinities
Authors: Martina Sykorov, Michelle Mojadi, Leyuan Bao, Eric GschwengMilena Kalaitsidou, Gray Kueberuwa, Xingliang (Tim) ZhouRuben Alvarez-Rodriguez, John S. BridgemanPoster/Abstract Number: 282

Title: ITIL-306-201: First-in-Human Multicenter Phase 1a/1b Study of ITIL-306, an Autologous Tumour-Infiltrating Cell Therapy (TIL) Product, in Adults With Advanced Solid Tumors
Authors: Neighborhood Jeffrey, Armin Gobadi, John B. Liao, Adam Schönfeld, Scott S. Tykodi, Yizhou Jiang, John Le Gall, Ruben Alvarez-Rodriguez, Marika Sherman, Tiffany Singson, Jeff McLeroyPoster/Abstract Number: 776

The posters are available in the publications section of the Instill Organic website: www.instilbio.com/publications.

About Instill Organic
Instill Bio, Inc. (Nasdaq: TIL) is a clinical-stage biopharmaceutical company focused on developing TIL therapies for the treatment of cancer patients. The company has assembled an accomplished management team with a successful track record in the development, manufacturing and commercialization of cell therapies. Using the company’s proprietary, optimized and scalable manufacturing processes at its in-house manufacturing facilities, Instil is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma and other solid tumors, as well as ITIL -306, a next-generation, genetically engineered TIL therapy for multiple solid tumors. For more information, visit www.instilbio.com and LinkedIn.

Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “expects”, “future”, “intends to ”, “potential”, “plans”, and “will” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements regarding or involving the potential of our product candidates to positively impact quality of life and alter the course of disease in the patients we seek to treat, our plans for research, development and regulatory requirements for our product candidates, the timing of our ongoing and potential future clinical trials and studies and the availability of data therefrom, including our expectations regarding the clinical exploration of ITIL-306 in multiple types of solid tumors with a variety of FRα expression levels, the expected safety profile of the CoStAR platform, and other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements, including risks and uncertainties associated with the cost and time involved in the cell therapy product development process and the uncertainty of clinical success, including risks associated with failure or delays in launch, registration, data reporting or completion clinical studies, as well as the risks that results obtained in clinical trials to date may not be indicative of results obtained in ongoing or future trials and that Instil’s product candidates may otherwise not be effective treatments in their intended indications; the ongoing COVID-19 pandemic, which could materially and adversely affect Instil’s business and operations, including Instil’s ability to timely initiate, enroll and complete its ongoing and future clinical trials; the lengthy and uncertain regulatory approval process; risks inherent in manufacturing and testing cell therapy products; the sufficiency of Instil’s cash resources, and other risks and uncertainties affecting Instil and its development programs, including those discussed in the section titled “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 available on the SEC’s website at www.sec.gov, and in other filings we make from time to time with the SECOND. These risks may be amplified by the impacts of the COVID-19 pandemic. Accordingly, these forward-looking statements are not guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and we undertake no obligation to update these statements, except as required by law.

contacts:
Media Contact:
1-833-446-7845 Ext. 1009
mediarelations@instilbio.com

Janhavi MohiteSerious investor relations
1-212-362-1200
janhavi.mohite@sternir.com

main logo

Source: Instill Organic

2022 GlobeNewswire, Inc., source Press Releases